Edesa Biotech

Edesa Biotech

Edesa Biotech is a Markham, Ontario-based biotechnology company working on non-steroidal topical treatment alternatives for inflammatory and autoimmune diseases. Edesa Biotech is a wholly owned subsidiary of Stellar Biotechnologies.

Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. Their initial focus is on developing novel, safe and potent alternatives to steroids for allergic contact dermatitis, hemorrhoids, and anal fissures. Edesa Biotech's lead asset, EB01 is a novel non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies.

Clinical Pipeline

As of April 2020, Edesa Biotech's clinical pipeline includes their EB01 topical treatment for contact dermatitis which was in Phase 2 of clinical trials; their EB01 topical treatment for hemorrhoids which was in Phase 1 of clinical trials; their EB04 topical treatment for anal fissures which was in Phase 1 of clinical trials; their EB05 and EB06 acute respiratory distress syndrome mAb treatment which were both in Phase 2 of clinical trials; and their immunotherapy for vitiligo which was heading into lead optimization as of April, 2020.

Stellar Biotechnology Merger

In May 2019, Stellar Biotechnologies shareholders approved a reverse merger with Edesa Biotech, in which the privately owned Edesa Biotech was brought onto the public market under Stellar Biotechnologies shares on the NASDAQ. As per the terms of the agreement, Edesa Biotech shareholders exchanged their shares for newly issued shares of Stellar. Edesa Biotech shareholders would own 90% of the new company. The new company retains Edesa Biotech's name, but the company has become a wholly owned subsidiary of Stellar Biotechnologies.

Timeline

September 20, 2017
Edesa Biotech raises a $7,000,000 series A round from Pharmascience, Lumira Ventures and Inveready Technology Investment Group.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Edesa Biotech funding round, September 2017
7,000,000
September 20, 2017
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Blair Gordon, PhD

Vice President, Research and Development

Gary Koppenjan

Vice President, Investor Relations and Communications

Kathi Niffenegger, CPA

Chief Financial Officer

Par Nijhawan, MD, FRCPC, AGAF

Chief Executive Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
November 30, 2020
BioSpace
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2/Phase3 clinical trial evaluating the companys investigational drug, EB05, as a therapy for hospitalized COVID-19 patients.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.